Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAN PARSA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1215268362
CMS profile
9273
Location
HONOLULU, HI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$63,184.04

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAN PARSA

NPI 1215268362 · CMS profile ID 9273

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

HONOLULU, HI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215268362?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAN PARSA, NPI 1215268362, CMS profile ID 9273. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215268362?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALAN PARSA, NPI 1215268362, CMS profile ID 9273. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215268362?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALAN PARSA, NPI 1215268362, CMS profile ID 9273, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1215268362?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $63,184.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $16.3204/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135995734 CMS
Eli Lilly and Company $105.3104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135995736 CMS
Eli Lilly and Company $1,107.9504/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135995740 CMS
Eli Lilly and Company $34.6904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135995742 CMS
Eli Lilly and Company $24.8104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136011549 CMS
Eli Lilly and Company $54.4404/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136012653 CMS
Eli Lilly and Company $59.8604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136012655 CMS
Eli Lilly and Company $24.8104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136012657 CMS
Eli Lilly and Company $59.8604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136013780 CMS
Eli Lilly and Company $54.7504/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136013988 CMS
Eli Lilly and Company $105.0004/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136013990 CMS
Eli Lilly and Company $34.6904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136015107 CMS
Eli Lilly and Company $24.8104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136015109 CMS
Eli Lilly and Company $7.3504/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136015111 CMS
Eli Lilly and Company $5.4004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136016519 CMS
Eli Lilly and Company $24.8104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136016521 CMS
Eli Lilly and Company $322.9404/25/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155177043 CMS
Eli Lilly and Company $450.2704/25/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155184297 CMS
Novo Nordisk Inc $938.0004/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096586851 CMS
Corcept Therapeutics $141.2904/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117738736 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $97.6504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918075 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $265.8004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918085 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $402.1104/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918089 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,050.0004/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918093 CMS
Novo Nordisk Inc $14.8404/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097485022 CMS
Novo Nordisk Inc $114.9904/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096871203 CMS
Novo Nordisk Inc $2,437.5004/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097363324 CMS
Novo Nordisk Inc $125.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097443457 CMS
Bayer Healthcare Pharmaceuticals Inc. $11.7304/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086090359 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,900.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918097 CMS
Amgen Inc. $18.5504/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111670920 CMS
Novo Nordisk Inc $1,595.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097151737 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.3703/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918049 CMS
Novo Nordisk Inc $14.7203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097504377 CMS
Abbott Laboratories $0.9003/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124903231 CMS
Abbott Laboratories $19.8903/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124903233 CMS
Abbott Laboratories $19.8803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124903235 CMS
Abbott Laboratories $0.9703/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124903237 CMS
Abbott Laboratories $0.7603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124903239 CMS
RECORDATI_RARE_DISEASES_INC. $20.6403/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139165482 CMS
Insulet Corporation $21.4703/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116792965 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $122.3403/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918079 CMS
Corcept Therapeutics $12.4103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117738730 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $40.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918065 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $40.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918067 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $50.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918069 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $50.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918071 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $185.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918081 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $336.5903/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117918087 CMS
Novo Nordisk Inc $23.9203/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096886271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $72,407.81 289
PY2020 $59,630.08 156
PY2021 $67,552.80 192
PY2022 $116,152.05 239
PY2023 $48,126.33 199
PY2024 $63,184.04 170
PY2025 $157,283.75 188

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,036,292.60 25
PY2024 Recipient $93,997.00 4
PY2024 Principal investigator $1,319,373.09 19
PY2023 Recipient $1,333.38 3
PY2023 Principal investigator $713,335.51 20
PY2022 Recipient $446.00 1
PY2022 Principal investigator $184,025.00 7
PY2021 Recipient $86,960.15 2
PY2021 Principal investigator $210,656.15 13
PY2019 Recipient $2,957.53 2
PY2019 Principal investigator $59,001.95 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
PACIFIC DIABETES & ENDOCRINE CENTER
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532767
Principal investigator 1 ABBVIE INC. $26,584.20 12/05/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529302
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,600.00 11/25/2025 Non-covered Recipient Entity
Pacific Diabetes And Endocrine Center
BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. No dispute reported 06/30/2026 1225419843
Principal investigator 1 ABBVIE INC. $23,367.15 11/05/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521535
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,164.50 11/01/2025 Non-covered Recipient Entity
Pacific Diabetes And Endocrine Center
BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. No dispute reported 06/30/2026 1225419735
Principal investigator 1 ABBVIE INC. $17,050.50 10/09/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514237
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,368.00 09/19/2025 Non-covered Recipient Entity
Pacific Diabetes And Endocrine Center
BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. No dispute reported 06/30/2026 1225419819
Principal investigator 1 ABBVIE INC. $19,522.35 09/04/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508722
Principal investigator 1 ABBVIE INC. $13,258.35 08/06/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502638
Principal investigator 1 ABBVIE INC. $7,079.40 07/02/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495327
Principal investigator 1 Eli Lilly and Company $237,227.66 06/09/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187888306
Principal investigator 1 Eli Lilly and Company $1.65 06/09/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187889906
Principal investigator 1 ABBVIE INC. $7,882.65 06/03/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488871
Principal investigator 1 ABBVIE INC. $11,126.70 05/07/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483971
Principal investigator 1 ABBVIE INC. $3,030.75 04/03/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CTR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202468996
Principal investigator 1 Eli Lilly and Company $92,547.00 01/21/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187887744
Principal investigator 1 Eli Lilly and Company $694.13 01/19/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187887748
Principal investigator 1 Eli Lilly and Company $589.44 01/17/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187889352
Principal investigator 1 Eli Lilly and Company $4,971.12 01/09/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187889350
Principal investigator 1 Eli Lilly and Company $8,535.40 01/09/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187889740
Principal investigator 1 Eli Lilly and Company $148,591.00 01/07/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187887746
Principal investigator 1 Eli Lilly and Company $264,209.00 01/07/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187889348
Principal investigator 1 Eli Lilly and Company $91,673.00 01/07/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187889738
Principal investigator 1 Eli Lilly and Company $41,928.00 01/07/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187889904
Principal investigator 1 Eli Lilly and Company $1,770.65 01/06/2025 Non-covered Recipient Entity
PACIFIC DIABETES AND ENDOCRINE CENTER
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187887484